AI drug development startup Pathos AI closes $237M investment

Pathos AI Inc. today announced that it has raised $237 million in funding at a $3 billion valuation. Pharmaceutical giant ...
kucoin

AI pharmaceutical company Pathos AI completes a $237 million Series E round, valued at $3 billion

AI pharmaceutical company Pathos AI has completed a $237 million Series E funding round, bringing its post-money valuation to ...
kucoin

Pathos AI Completes $237M Series E Funding, Valued at $3B

AI pharmaceutical company Pathos AI has completed a $237 million Series E funding round, bringing its post-money valuation to ...
TipRanks

Pathos AI enters collaborations with Bristol Myers, Tempus AI

Pathos AI announced multi-year strategic collaborations with Bristol Myers Squibb (BMY) and Tempus AI (TEM) to build a specialized, curated dataset and agentic AI ...
MarketScreener

Pathos AI Announces Strategic Collaborations With Bristol Myers Squibb And Tempus AI, Inc. To Advance AI-Driven Drug Development Beginning With Alzheimer?s Disease And Other ...

Pathos AI announced multi-year strategic collaborations with Bristol Myers Squibb and Tempus AI, Inc. to build a specialized, curated dataset and agentic AI capabilities for Alzheimer?s disease and ...
techtimes

Pathos AI Closes $2.3B Cancer Drug Deals to Prove AI Can Design Smarter Trials

In a single news cycle, Pathos AI announced two simultaneous drug licensing agreements worth up to $2.3 billion in combined milestones — and disclosed that it is targeting a $300 million Series E ...
SiliconANGLE

AI-powered drug development startup Pathos AI closes $365M investment

Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised $365 million in a late-stage funding. The company didn’t disclose the ...